XML 29 R16.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets Disclosure [Text Block] | INTANGIBLE ASSETS AND GOODWILL The following table summarizes the carrying amount of our Intangible assets, net (in millions):
|  | December 31,
|  | 2017 |  | 2016
Finite-lived intangible assets |  | $ | 14,350 |  |  | $ | 8,971 |
Indefinite-lived intangible assets |  | 2,750 |  |  | — |
Total |  | $ | 17,100 |  |  | $ | 8,971 |
Finite-Lived Intangible Assets The following table summarizes our finite-lived intangible assets (in millions):
|  | December 31, 2017 |  | December 31, 2016
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | 2,855 |  |  | $ | 7,865 |  |  | $ | 10,720 |  |  | $ | 2,156 |  |  | $ | 8,564 |
Intangible asset - axicabtagene ciloleucel (DLBCL) |  | 6,200 |  |  | 72 |  |  | 6,128 |  |  | — |  |  | — |  |  | — |
Intangible asset - Ranexa |  | 688 |  |  | 566 |  |  | 122 |  |  | 688 |  |  | 467 |  |  | 221 |
Other |  | 546 |  |  | 311 |  |  | 235 |  |  | 455 |  |  | 269 |  |  | 186 |
Total |  | $ | 18,154 |  |  | $ | 3,804 |  |  | $ | 14,350 |  |  | $ | 11,863 |  |  | $ | 2,892 |  |  | $ | 8,971 |
Amortization expense related to finite-lived intangible assets, included primarily in Cost of goods sold on our Consolidated Statements of Income, totaled $912 million, $844 million and $826 million in 2017, 2016 and 2015. As of December 31, 2017, estimated future amortization expense associated with our finite-lived intangible assets is as follows (in millions):
Fiscal Year | Amount
2018 | $ | 1,203 |
2019 | 1,088 |
2020 | 1,064 |
2021 | 1,064 |
2022 | 1,064 |
Thereafter | 8,867 |
Total | $ | 14,350 |
Indefinite-Lived Intangible Assets As of December 31, 2017, we had indefinite-lived intangible assets of $2,750 million, which consisted of the purchased IPR&D from our acquisition of Kite. See Note 5, Acquisitions for additional information. In 2016, the estimated fair value of our IPR&D related to momelotinib and simtuzumab was written down to zero due to termination of clinical development of such programs, and as a result, we recorded impairment charges of $432 million within Research and development expenses on our Consolidated Statements of Income. Goodwill Upon completing the acquisition of Kite in October 2017, we preliminarily attributed $2,987 million to goodwill on our Consolidated Balance Sheets. The following table summarizes the changes in the carrying amount of goodwill (in millions):
Balance at December 31, 2016 | $ | 1,172 |
Goodwill resulting from the acquisition of Kite | 2,987 |
Balance at December 31, 2017 | $ | 4,159 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration